logo
logo
PTCT stock ticker logo

PTC Therapeutics, Inc.

NASDAQ•PTCT
CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2013-06-20
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Contact Information
100 Corporate Court, South Plainfield, NJ, 07080, United States
908-222-7000
www.ptcbio.com
Market Cap
$5.24B
P/E (TTM)
7.5
17.5
Dividend Yield
--
52W High
$87.50
52W Low
$35.95
52W Range
53%
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$164.68M+0.00%
4-Quarter Trend

EPS

-$1.67+0.00%
4-Quarter Trend

FCF

-$36.65M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Significant Net Income Swing Net income reached $682.6M USD in 2025, reversing prior year loss of $(363.3)M USD; driven by large upfront payments.
Collaboration Revenue Surge Collaboration revenue hit $998.4M USD, up significantly from $0.3M USD in 2024, due to Novartis votoplam deal closing.
New Product Revenue Starts Sephience revenue $111.2M USD recognized in 2025 following EC and FDA approvals across multiple geographies.
Product Sales Remain Stable Total net product revenue $586.7M USD, stable versus 2024; Emflaza sales declined due to generic competition.

Risk Factors

Translarna EEA Authorization Risk Loss of Translarna nmDMD marketing authorization in EEA poses substantial risk to EEA revenue generation.
Emflaza Generic Competition Emflaza orphan exclusivity expired February 2024, leading to increased generic competition and revenue impact.
Continued Operating Expense Expect continued significant operating expenses for foreseeable future; profitability remains uncertain without sustained revenue.
Manufacturing Supply Chain Reliance Reliance on third-party manufacturers for critical products like Translarna and Sephience presents supply chain risks.

Outlook

Votoplam Phase 3 Trial Planned Novartis expects to initiate global Phase 3 votoplam trial for Huntington's disease in first half of 2026.
Vatiquinone NDA Resubmission Study Plan to meet FDA Q2 2026 to discuss design for required additional study supporting vatiquinone NDA resubmission.
Future Capital Requirements Depend Future capital needs depend heavily on commercializing products and satisfying obligations under 2026 Convertible Notes.
Expanding International Commercialization Anticipate continued significant expenses for expanding commercialization efforts across US, EEA, Latin America, and Japan.

Peer Comparison

Revenue (TTM)

PTCT stock ticker logoPTCT
$1.73B
+114.5%
ALKS stock ticker logoALKS
$1.48B
-5.2%
ARWR stock ticker logoARWR
$1.09B
+4081.8%

Gross Margin (Latest Quarter)

CRNX stock ticker logoCRNX
111.8%
+0.0pp
ARWR stock ticker logoARWR
100.0%
+50.6pp
PTGX stock ticker logoPTGX
94.9%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PCVX$8.09B-10.0-25.9%7.5%
ARWR$7.70B38.136.1%19.5%
KRYS$7.35B35.518.7%0.7%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-48.1%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Deep Research

Next earnings:Apr 23, 2026
|
EPS:-$0.44
|
Revenue:$222.78M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data